Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia

Value in Health

Volumn 12, Issue 8, 2009, Pages 1135-1143

  Friedman, Howard ^a   Song, Xue ^b   Crespi, Simone ^c   Navaratnam, Prakash ^d  

^a Analytic Solutions LLC   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Informagenics LLC   (United States)

Author keywords

Community acquired pneumonia; Cost; Hospital; Length of stay; Levofloxacin; Moxifloxacin; Treatment outcomes

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG COST; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 70350776530     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00576.x     Document Type: Article

References (23)

1. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998 20 : 820 837.
2. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 2007 55 : 1 119.
3. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am 2004 18 : 761 776.
4. DeFrances CJ, Hall MJ. 2005 National hospital discharge survey. Adv Data 2007 385 : 1 19.
5. Healthcare Cost and Utilization Project (HCUP). 2005 HCUP Nationwide Inpatient Sample (NIS) Comparison Report. Available from : http://www.hcup-us. ahrq.gov/reports/methods.jsp [Accessed March 19, 2008 LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 44 (Suppl. 2 S27 72.
6. Merchant S, Mullins CD, Shih Y-CT. Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther 2003 25 : 593 610.
7. Orrick JJ, Segal R, Johns TE, et al. Resource use and cost of care for patients hospitalized with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 2004 22 : 751 757.
8. Wu JH, Howard DH, McGowan JE Jr., et al. Adherence to Infectious Diseases Society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort. Clin Ther 2006 28 : 1451 1461.
9. Fine MJ, Pratt HM, Obrosky S, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000 109 : 378 385.
10. McCormick D, Fine MJ, Coley CM, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999 107 : 5 12.
11. File TM Jr., Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997 41 : 1965 1972.
12. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002 46 : 1746 1754.
13. Welte T, Petermann W, Schürmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005 41 : 1697 1705.
14. Anzueto A, Niederman MS, Pearle J, et al., for the Community-Acquired Pneumonia Recovery for the Elderly Study Group. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006 42 : 73 81.
15. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000 283 : 749 755.
16. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential iv/po moxifloxacin therapy compared with iv/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003 124 : 526 535.
17. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005 128 : 2238 2248.
18. Schein J, Janagap-Benson C, Grant R, et al. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin 2008 24 : 895 906.
19. Premier Perspective. Available from: http://www.premierinc.com/quality- safety/tools-services/prs/services/perspectiverx.jsp [Accessed March 18, 2008 2008. Available from: http://www.avelox.com/html/pdf/avelox-prescribing.pdf [Accessed March 18, 2008 2008. Available from: http://www.levaquin.com/levaquin/ shared/pi/levaquin.pdf#zoom=100 [Accessed March 18, 2008 JJ, Ichimura H, Todd P. Matching as an economic evaluation estimator: evidence from evaluating a job training programme. Rev Econ Studies 1997 64 : 605 654.
20. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In : Proceedings of the 25th annual SAS Users Group international conference, April 22-23, 2001, Long Beach, CA. Cary, NC : SAS Institute 2001 : 214 226.
21. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006 9 : 377 385.
22. Delhejia RH, Wahba S. Propensity score matching methods for nonexperimental causal studies. Rev Econ Stat 2002 84 : 151 161.
23. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008 27 : 2037 2049.